European Medicines Agency (EMA) Updates For patients in Europe, access to new medications is governed by the European Medicines Agency (EMA)
Viking Therapeutics Sector: Dual and triple agonists for obesity, metabolic, and liver disease HQ: San Diego, CA Year Founded: 2012 Origin Story: The company built its pipeline around small molecule and peptide candidates licensed from academic and pharma sources, eventually advancing VK2735, a dual GLP-1/GIP receptor agonist designed to be the first such therapy available in both oral and injectable formulations
Deane AM, Chapman MJ, Horowitz M
Do GLP patches work for weight loss
Exendin-4 ameliorates high glucose-induced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells
Thus we proposed the central idea of our commentary: Chronic glucagon suppression may shift amino-acid handling toward muscle proteolysis, creating a silent but progressive erosion of muscle reserve